By Karen Roman
Agendia, Inc., a biotechnology company that provides molecular diagnostics and cancer treatment, said it can predict response and nonresponse to common neoadjuvant immunotherapy for patients with triple negative breast cancer.
Agendia holds an FDA Investigational Device Exempt status for its ImPrint signature, allowing its use in ongoing research, the company said.
“The data we are presenting at the European Breast Cancer Conference demonstrates ImPrintTN’s predictive ability to help patients with triple negative breast cancer avoid immunotherapy if they are not likely to benefit,” said Co-Founder Laura van ‘t Veer. “These insights are critical and can be used to inform alternative treatment strategies and customize our approach to meet the needs of each patient’s cancer diagnosis.”
